{
    "nct_id": "NCT04093596",
    "official_title": "A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma",
    "inclusion_criteria": "* Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (serum, urine, or free light chain [FLC]) per International Myeloma Working Group (IMWG) criteria\n* At least 3 prior lines of MM therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody (unless contraindicated), and refractory to the last treatment line.\n* Eastern Cooperative Oncology Group (ECOG) 0 or 1\n* Absence of donor (product)-specific anti-HLA antibodies\n* Adequate hematologic, renal, hepatic, pulmonary, and cardiac function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current or history of Central Nervous System (CNS) involvement of myeloma or plasma cell leukemia\n* Clinically significant CNS disorder\n* Current or history of thyroid disorder\n* Autologous stem cell transplant within the last 6 weeks, or any allogeneic stem cell transplant\n* Prior treatment with anti-BCMA therapy, any gene therapy, any genetically modified cell therapy, or adoptive T cell therapy\n* History of HIV infection or acute or chronic active hepatitis B or C infection\n* Patients unwilling to participate in an extended safety monitoring period\n\nAdditional Exclusion Criteria for Nirogacestat plus ALLO-715 Cohorts\n\n* Inability to swallow tablets\n* Subject has known malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat\n* Use of strong/moderate CYP3A4 inhibitors, and strong CYP3A4 inducers within 14 days before starting nirogacestat.\n* Use of concomitant medications that are known to prolong the QT/QTcF interval",
    "miscellaneous_criteria": ""
}